[CORT] Corcept Therapeutics Incorporated


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 8.12 Change: 0.21 (2.65%)
Ext. hours: Change: 0 (0%)

chart CORT

Refresh chart

Strongest Trends Summary For CORT

CORT is in the medium-term up 38% in 1 year. In the long-term up 449% in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Corcept Therapeutics Incorporated, a pharmaceutical company, is engaged in the discovery, development, and commercialization of drugs for the treatment of metabolic, psychiatric, and oncologic disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing?s syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing mifepristone, an active ingredient in Korlym, which is in Phase III study for treatment of the psychotic features of psychotic depression; and in Phase I study for the treatment of triple-negative breast cancer. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta D

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 72.68% Sales Growth - Q/Q12.07% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-46.21% ROE-210.77% ROI
Current Ratio2.85 Quick Ratio2.76 Long Term Debt/Equity0.77 Debt Ratio1.47
Gross Margin96.87% Operating Margin-58.27% Net Profit Margin-69.1% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities15.52 M Cash From Investing Activities-30 K Cash From Operating Activities-1.78 M Gross Profit9.8 M
Net Profit-4.83 M Operating Profit-4.03 M Total Assets48.22 M Total Current Assets44.19 M
Total Current Liabilities15.53 M Total Debt32.78 M Total Liabilities37.65 M Total Revenue10.1 M
Technical Data
High 52 week17.19 Low 52 week9.78 Last close14.36 Last change2.21%
RSI43.75 Average true range0.45 Beta0.99 Volume325.31 K
Simple moving average 20 days1.81% Simple moving average 50 days7.91% Simple moving average 200 days18.95%
Performance Data
Performance Week2.21% Performance Month8.05% Performance Quart34.58% Performance Half21.9%
Performance Year17.32% Performance Year-to-date7.49% Volatility daily1.61% Volatility weekly3.6%
Volatility monthly7.37% Volatility yearly25.52% Relative Volume267.92% Average Volume720.16 K
New High New Low


2020-06-03 11:30:03 | Has Corcept Therapeutics CORT Outpaced Other Medical Stocks This Year?

2020-06-03 11:30:03 | Why Is Corcept CORT Up 8.2% Since Last Earnings Report?

2020-05-18 06:23:06 | Should You Worry About Corcept Therapeutics Incorporated's NASDAQ:CORT CEO Pay?

2020-05-14 16:05:10 | Corcept Therapeutics to Present Data at the American Society of Clinical Oncology Annual Meeting

2020-05-13 13:16:24 | 6 Stocks John Hussman Continues to Buy

2020-05-12 07:45:00 | Should You Climb on Board the Corcept Therapeutics Train?

2020-05-10 22:46:10 | Were Hedge Funds Right About Corcept Therapeutics Incorporated CORT?

2020-05-06 18:27:00 | Corcept Therapeutics Shows Rising Price Performance With Jump To 85 RS Rating

2020-05-05 20:26:46 | Edited Transcript of CORT earnings conference call or presentation 4-May-20 9:00pm GMT

2020-05-05 14:50:06 | Corcept CORT Q1 Earnings Top Estimates, Revenues Rise Y/Y

2020-05-05 08:31:12 | New Strong Buy Stocks for May 5th

2020-05-05 01:02:01 | Corcept Therapeutics Incorporated CORT Q1 2020 Earnings Call Transcript

2020-05-04 19:05:11 | Corcept Therapeutics CORT Tops Q1 Earnings and Revenue Estimates

2020-05-04 16:05:10 | Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update

2020-04-27 16:05:10 | Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

2020-04-27 12:00:04 | Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics CORT is a Great Choice

2020-04-22 06:43:58 | Should You Be Adding Corcept Therapeutics NASDAQ:CORT To Your Watchlist Today?

2020-04-13 08:31:12 | Corcept Therapeutics' Shares March Higher, Can It Continue?

2020-04-02 09:51:01 | Why You Shouldn't Bet Against Corcept Therapeutics CORT Stock


2020-03-26 12:06:34 | Update: Corcept Therapeutics NASDAQ:CORT Stock Gained 88% In The Last Five Years

2020-03-21 11:30:03 | Corcept CORT Down 24.9% Since Last Earnings Report: Can It Rebound?

2020-03-12 08:30:10 | Corcept Therapeutics Appoints Gregg Alton to Board of Directors

2020-03-03 09:00:28 | These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why

2020-02-25 06:22:54 | An Intrinsic Calculation For Corcept Therapeutics Incorporated NASDAQ:CORT Suggests It's 25% Undervalued

2020-02-24 12:41:00 | Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated CORT

2020-02-21 14:25:07 | Corcept CORT Q4 Earnings In-Line with Estimates, Up Y/Y

2020-02-20 18:15:11 | Corcept Therapeutics CORT Meets Q4 Earnings Estimates

2020-02-20 16:05:10 | Corcept Therapeutics Announces Fourth Quarter And Full-Year 2019 Audited Financial Results And Provides Corporate Update

2020-02-19 12:10:05 | Why Corcept CORT Could Beat Earnings Estimates Again

2020-02-18 11:04:04 | What's in Store for Corcept CORT This Earnings Season?

2020-02-17 12:30:05 | Corcept Therapeutics CORT to Report Q4 Results: What Awaits?

2020-02-13 16:05:10 | Corcept Therapeutics to Announce Audited Financial Results, Provide Corporate Update and Host Conference Call

2020-01-30 16:06:10 | Corcept Therapeutics Announces Fourth Quarter and Full-Year 2019 Preliminary Selected Financial Results; Provides 2020 Revenue Guidance

2020-01-30 06:45:53 | How Corcept Therapeutics Incorporated NASDAQ:CORT Can Impact Your Portfolio Volatility

2020-01-09 08:40:01 | Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study

2020-01-08 10:18:03 | Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up

2020-01-07 10:21:03 | Soleno SLNO Ends Enrollment in Prader-Willi Syndrome Study

2020-01-07 09:51:02 | Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA

2020-01-07 09:17:02 | Catalyst Gives Preliminary Firdapse Estimates & Other Updates

2020-01-07 07:54:12 | New Strong Buy Stocks for January 7th

2019-12-31 07:49:35 | Read This Before Selling Corcept Therapeutics Incorporated NASDAQ:CORT Shares

2019-12-26 19:25:00 | Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Corcept Therapeutics Incorporated CORT

2019-12-10 10:46:43 | Hedge Funds Are Buying Corcept Therapeutics Incorporated CORT

2019-12-07 11:31:04 | Why Is Corcept CORT Down 8.9% Since Last Earnings Report?

2019-12-04 07:43:58 | Why Corcept Therapeutics Incorporated's NASDAQ:CORT High P/E Ratio Isn't Necessarily A Bad Thing

2019-11-19 08:51:01 | Can The Uptrend Continue for Corcept Therapeutics?

2019-11-14 08:52:01 | Options Traders Expect Huge Moves in Corcept CORT Stock

2019-11-08 18:08:00 | Edited Transcript of CORT earnings conference call or presentation 7-Nov-19 10:00pm GMT

2019-11-08 10:31:03 | Corcept CORT Earnings Beat in Q3, Korlym Boosts Sales